RBC Capital Maintains Outperform on OptimizeRx, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge has maintained an 'Outperform' rating on OptimizeRx (NASDAQ:OPRX) but lowered the price target from $18 to $14.

August 15, 2023 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
OptimizeRx's price target has been lowered from $18 to $14 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital indicates a potential decrease in the short-term value of OptimizeRx's stock. However, the maintained 'Outperform' rating suggests that the stock is still expected to outperform the market or its sector, which could mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100